<DOC>
	<DOCNO>NCT02427243</DOCNO>
	<brief_summary>To assess relative bioavailability tolerability two different formulation crenezumab approximately 60 healthy volunteer .</brief_summary>
	<brief_title>A Study Healthy Volunteers Assess Relative Bioavailability Tolerability Two Crenezumab Formulations Following Administration Single Subcutaneous Dose</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Healthy male female 18 65 year age Screening , inclusive Body mass index ( BMI ) 18.5 32 kg/m^2 , inclusive Body weight 50 100 kg , inclusive Females must nonchildbearing potential Males reproductive potential must agree remain abstinent must use highly effective contraception must avoid sperm donation , Screening least 8 week last study drug administration study completion , whichever later Significant medical history , psychiatric disorder , acute infection Screening ( determine Investigator ) History alcoholism drug addiction within 6 month prior CRU Checkin Use tobacco nicotinecontaining product 6 month prior CRU Checkin study Participation investigational study drug trial receipt investigational study drug occur wtihin 30 day 5 halflives , whichever longer , prior CRU Checkin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>